Limited capability for testing mycobacterium tuberculosis for susceptibility to new drugs

Hamzah Z. Farooq, Daniela M. Cirillo, Doris Hillemann, David Wyllie, Marieke J. Van der Werf, Csaba Ködmön, Vladyslav Nikolayevskyy

Research output: Contribution to journalLetterpeer-review

Abstract

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.

Original languageEnglish
Pages (from-to)985-987
Number of pages3
JournalEmerging Infectious Diseases
Volume27
Issue number3
DOIs
Publication statusPublished - Mar 2021

Fingerprint

Dive into the research topics of 'Limited capability for testing mycobacterium tuberculosis for susceptibility to new drugs'. Together they form a unique fingerprint.

Cite this